Does clinical experience with a treatment regimen affect survival of lung cancer patients? An analysis based on consecutive randomized trials of the Medical Research Council in small cell and non-small cell tumours. Medical Research Council Lung Cancer Working Party
- PMID: 8018578
- DOI: 10.1016/s0936-6555(05)80109-8
Does clinical experience with a treatment regimen affect survival of lung cancer patients? An analysis based on consecutive randomized trials of the Medical Research Council in small cell and non-small cell tumours. Medical Research Council Lung Cancer Working Party
Abstract
This paper investigates the influence on patient survival of an individual clinician's experience with a particular treatment regimen and the collective experience of the centre through which the patient is recruited to a particular clinical trial. Data were available from two series of randomized trials, one series in small cell and the other in non-small cell lung cancer, which were conducted by the Medical Research Council Lung Cancer Working Party. Successive small cell trials used the same chemotherapy regimen and successive non-small cell trials the same radiotherapy regimen. We found no evidence that either the degree of experience of individual clinicians with the regimen or the participation in terms of number of patients recruited to centres influenced patient survival. There is a strong suggestion, in non-small cell lung cancer that, as clinicians' experience with the regimen extended, they became increasingly likely to admit patients in poor condition to the trials. We stress how important it is to take account of patient prognostic characteristics in such an analysis, as we found that unadjusted comparisons suggested negative influences of increasing experience with the regimen. The implications for routine audit are self evident, in particular that it is not a substitute for the randomized controlled trial.
Similar articles
-
Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party.Lung Cancer. 1994 Sep;11(3-4):259-74. doi: 10.1016/0169-5002(94)90546-0. Lung Cancer. 1994. PMID: 7812703
-
Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.Br J Cancer. 1989 Apr;59(4):584-90. doi: 10.1038/bjc.1989.118. Br J Cancer. 1989. PMID: 2540789 Free PMC article. Clinical Trial.
-
[Randomized controlled trials in Japan--lung cancer].Gan To Kagaku Ryoho. 2002 Sep;29(9):1516-21. Gan To Kagaku Ryoho. 2002. PMID: 12355937 Review. Japanese.
-
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.Br J Cancer. 1993 Dec;68(6):1150-6. doi: 10.1038/bjc.1993.496. Br J Cancer. 1993. PMID: 8260367 Free PMC article. Clinical Trial.
-
Lung cancer.Clin Evid. 2002 Jun;(7):1369-83. Clin Evid. 2002. Update in: Clin Evid. 2002 Dec;(8):1558-74. PMID: 12230752 Updated. Review. No abstract available.
Cited by
-
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results.Br J Cancer. 2002 Aug 27;87(5):562-6. doi: 10.1038/sj.bjc.6600433. Br J Cancer. 2002. PMID: 12189557 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
